Tracon Pharmaceuticals Inc. reported that adding its lead candidate, TRC105 (carotuximab), to Avastin (bevacizumab) didn't appear to help patients with recurrent glioblastoma enjoy any more time without a worsening of their condition than Avastin monotherapy does.